Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide

Rhea-AI Summary

Daxor (Nasdaq: DXR) announces the expansion of its blood volume analysis (BVA) technology to three new facilities. The company's ezBVA lab service, a CLIA-certified facility providing next-day results, is spearheading growth and broader market adoption. Recent sales wins include:

• A leading medical center in Georgia adopting ezBVA Lab service
• A North Carolina hospital purchasing a blood volume analyzer
• A top-rated Central Florida hospital implementing ezBVA Lab service

Daxor anticipates accelerated sales growth for the rest of the year. The company's Sr. VP of Commercialization and Customer Experience, Jean Oertel, emphasized that their diagnostic solution helps healthcare facilities enhance patient care while managing expenses. The increasing adoption of Daxor's BVA technology highlights its critical impact on advancing treatment effectiveness for fluid management.

Positive

• Expansion to three new facilities, indicating market growth
• Anticipated accelerated sales growth for the rest of the year
• Increasing adoption of BVA technology in healthcare facilities

Negative

• None.

Daxor's ezBVA Lab Service Spearheads Growth and Broader Market Adoption

Oak Ridge, TN, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the expansion of blood volume analysis (BVA) in three new facilities. Daxor’s ezBVA lab service is a state-of-the-art CLIA certified facility that provides on-demand, next day blood volume analysis results. The company anticipates sustained accelerated sales growth during the rest of the year.

Recent sales wins include:

• Leading full-service medical center in Georgia adopts Daxor’s ezBVA Lab service.
• Second hospital, part of the largest non-profit health system in North Carolina, purchases a blood volume analyzer.
• Top-rated Central Florida hospital implements Daxor's ezBVA Lab service.

“Providing efficient and effective options to implement our diagnostic solution empowers healthcare facilities to meet the dual challenges of enhancing patient care and managing expenses,” said Jean Oertel, Sr. VP Commercialization and Customer Experience. “The increase in adoption of our blood volume analysis technology underscores its critical impact in advancing treatment effectiveness for fluid management and is driving further sales growth for the company.”

About Daxor Corporation 
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements 
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com

FAQ

What is Daxor's stock symbol?

Daxor 's stock symbol is DXR, and it is listed on the Nasdaq exchange.

How many new facilities has Daxor expanded to in August 2024?

Daxor has expanded its blood volume analysis (BVA) technology to three new facilities in August 2024.

What is Daxor's ezBVA Lab service?

Daxor's ezBVA Lab service is a CLIA-certified facility that provides on-demand, next-day blood volume analysis results.

Which states are mentioned in Daxor's recent sales wins?

The recent sales wins mentioned in the press release include facilities in Georgia, North Carolina, and Florida.